¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"ü"¿¡ ´ëÇÑ ´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
9
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
somatic crossing over
ü¼¼Æ÷ ±³Â÷(ô÷á¬øàÎßó©)
somatic mutation
ü¼¼Æ÷ º¯ÀÌ(ô÷á¬øàܨì¶)
somatic mutation theory
ü¼¼Æ÷ º¯ÀÌÀÌ·Ð(ô÷á¬øàܨì¶×âÖå)
somatic cell genetic engineering
ü¼¼Æ÷ À¯Àü°øÇÐ(ô÷á¬øàë¶îîÍïùÊ)
somatic theory
ü¼¼Æ÷ ÀÌ·Ð(ô÷á¬øà×âÖå)
somatic recombination theory
ü¼¼Æ÷ ÀçÁ¶ÇÕ ÀÌ·Ð(ô÷á¬øàî¢ðÚùê×âÖå)
somatic cell
ü¼¼Æ÷(ô÷á¬øà)
somatic cell hybrid
ü¼¼Æ÷(ô÷á¬øà) Æ¢±â
explant
ü¿ÜÀÌ½Ä Á¶Á÷ (ô÷èâì¹ãÕðÚòÄ)
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
absolute configuration
Àý´ëÀÔüÇü»ó±¸Á¶ (ï¾Óßí¡ô÷û¡ßÀϰðã)
absorber
Èí¼öü (ýåâ¥ô÷)
acceptor control
¼ö¿ëü Á¦¾î (â¥é»ô÷ ð¤åÙ)
acceptor-control ratio
¼ö¿ëü Á¦¾îÀ² (â¥é»ô÷ ð¤åÙëÒ)
accumulator organism
´©Àû°³Ã¼ (ÒéîÝËÁô÷)
acetone body
¾Æ¼¼ÅæÃ¼(ô÷)
acquired antibody
"ȹµæÇ×ü (üòÔðù÷ô÷), ÈÄõ¼ºÇ×ü (ýô¸àõù÷ô÷)"
actin-myosin comolex
¾Çƾ¸¶ÀÌ¿À½Å º¹ÇÕü (ÜÜùêô÷)
acyl enzyme intermediates
¾Æ½ÇÈ¿¼Ò Áß°£Ã¼(ñéÊàô÷)
addition polymer
ºÎ°¡ÁßÇÕü(ݾʥñìùêô÷)
adenohypophsis
¼±³úÇϼöü(àÍÒàù»á÷ô÷)
adrenergic receptor
¾Æµå·¹³¯¸°ÀÛµ¿(íÂÔÑ) ¼ö¿ëü(áôé»ô÷)
aerial mycelium
È£±â¼º ±Õ»çü(û¿Ñ¨àõжÞêô÷)
agglutinating antibody
ÀÀÁýÇ×ü(ëêó¢ù÷ô÷)
aggregate
ÀÀÁýü(ëêó¢ô÷)
´ÙÀ½
ÅëÇÕ°Ë»ö ¿Ï·á
´ÙÀ½